From: Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
Toxicity
All grade
Grade 3-4
non-hematological
Fatigue
32.4%
0.1%*
Nausea
8.0%
0%
Vomiting
5.0%
Diarrhea
10.5%
Mucositis
4.5%
Sensorial neuropathy
2.4%
hematological
Anemia
44.0%
Leukopenia
3.2%
Neutropenia
4.0%